Cargando…

Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study

INTRODUCTION: Ipragliflozin is a novel antidiabetic drug that inhibits renal tubular sodium-glucose cotransporter-2 (SGLT2). The aim of this study was to evaluate the effects of ipragliflozin on glucose, insulin, glucagon, and gastrointestinal peptide responses to a meal tolerance test, as well as t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ueno, Hiroaki, Nakazato, Hiroko, Ebihara, Emi, Noma, Kenji, Kawano, Takahisa, Nagamine, Kazuhiro, Sakoda, Hideyuki, Nakazato, Masamitsu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801252/ https://www.ncbi.nlm.nih.gov/pubmed/29322485 http://dx.doi.org/10.1007/s13300-018-0366-8

Ejemplares similares

Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study
por: Ueno, Hiroaki, et al.
Publicado: (2015)

Current status of diabetes treatment in Miyazaki Prefecture, Japan: Results of a questionnaire survey conducted in 2016 and 2020
por: Uehira, Yudai, et al.
Publicado: (2022)

Concurrent Use of Teneligliptin and Canagliflozin Improves Glycemic Control with Beneficial Effects on Plasma Glucagon and Glucagon-Like Peptide-1: A Single-Arm Study
por: Noda, Tomoho, et al.
Publicado: (2019)

Is ghrelin a glucagon‐like peptide‐1 secretagogue?
por: Ueno, Hiroaki, et al.
Publicado: (2015)

Neuromedin U uses Gα(i2) and Gα(o) to suppress glucose-stimulated Ca(2+) signaling and insulin secretion in pancreatic β cells
por: Zhang, Weidong, et al.
Publicado: (2021)

Impaired adaptation of energy intake induces severe obesity in aged mice on a high‐fat diet
por: Okada, Tadashi, et al.
Publicado: (2019)

Mechanistic relationship between the vagal afferent pathway, central nervous system and peripheral organs in appetite regulation
por: Ueno, Hiroaki, et al.
Publicado: (2016)

Liver-expressed antimicrobial peptide 2 antagonizes the effect of ghrelin in rodents
por: Islam, Md Nurul, et al.
Publicado: (2019)

Human liver‐expressed antimicrobial peptide 2 elevation in the cerebrospinal fluid in bacterial meningitis
por: Sakai, Katsuya, et al.
Publicado: (2021)

Rapid pleural effusion after discontinuation of lenvatinib in a patient with pleural metastasis from thyroid cancer
por: Uchida, Taisuke, et al.
Publicado: (2019)

Restoration of metabolic inflammation-related ghrelin resistance by weight loss
por: Naznin, Farhana, et al.
Publicado: (2017)

Conformational Change in the Ligand-Binding Pocket via a KISS1R Mutation (P147L) Leads to Isolated Gonadotropin-Releasing Hormone Deficiency
por: Shimizu, Koichiro, et al.
Publicado: (2017)

Glycosuria medicated with ipragliflozin and nifedipine or ipragliflozin and candesartan: a case report
por: Okada, Shuichi, et al.
Publicado: (2014)

Body mass index and severity of parkinsonism in multiple system atrophy
por: Suzuki, Ai, et al.
Publicado: (2017)

Clinical Symptoms, Neurological Signs, and Electrophysiological Findings in Surviving Residents with Probable Arsenic Exposure in Toroku, Japan
por: Ishii, Nobuyuki, et al.
Publicado: (2018)

Long‐term efficacy of the sodium–glucose cotransporter 2 inhibitor, ipragliflozin, in a case of type A insulin resistance syndrome
por: Nagashima, Shuichi, et al.
Publicado: (2020)

Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes
por: Kutoh, Eiji, et al.
Publicado: (2016)

Diet-induced obesity causes peripheral and central ghrelin resistance by promoting inflammation
por: Naznin, Farhana, et al.
Publicado: (2015)

Liver-Expressed Antimicrobial Peptide 2 Is a Hepatokine That Predicts Weight Loss and Complete Remission of Type 2 Diabetes Mellitus after Vertical Sleeve Gastrectomy in Japanese Individuals
por: Nabekura, Hiroki, et al.
Publicado: (2023)

(18)F-fluorodeoxyglucose positron emission tomography and magnetic resonance imaging evaluation of chorea
por: Ishii, Nobuyuki, et al.
Publicado: (2018)

The sodium–glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes
por: Okura, Tsuyoshi, et al.
Publicado: (2022)

Neurons promote encephalitogenic CD4(+) lymphocyte infiltration in experimental autoimmune encephalomyelitis
por: Nakazato, Yuki, et al.
Publicado: (2020)

Potential for Gut Peptide-Based Therapy in Postprandial Hypotension
por: Borg, Malcolm J., et al.
Publicado: (2021)

Functional interaction between Ghrelin and GLP-1 regulates feeding through the vagal afferent system
por: Zhang, Weidong, et al.
Publicado: (2020)

A Japanese Case of CADASIL with a Rare Mutation in Exon 24 of the NOTCH3 Gene
por: Ebihara, Yuka, et al.
Publicado: (2018)

Ipragliflozin Ameliorates Diabetic Nephropathy Associated with Perirenal Adipose Expansion in Mice
por: Okuma, Hideyuki, et al.
Publicado: (2021)

Relationship between Fasting and Postprandial Glucose Levels and the Gut Microbiota
por: Mineshita, Yui, et al.
Publicado: (2022)

Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD
por: Takahashi, Hirokazu, et al.
Publicado: (2021)

Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring
por: Yamada, Kentaro, et al.
Publicado: (2015)

Detection of the KIAA1549-BRAF fusion gene in cells forming microvascular proliferations in pilocytic astrocytoma
por: Yamashita, Shinji, et al.
Publicado: (2019)

Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease
por: Miyake, Teruki, et al.
Publicado: (2018)

Ipragliflozin/tozinameran: Diabetic ketoacidosis: 2 case reports
Publicado: (2022)

Pharmacological inhibition of diacylglycerol acyltransferase-1 and insights into postprandial gut peptide secretion
por: Maciejewski, Benjamin S, et al.
Publicado: (2017)

The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin
por: Takeda, Akihiko, et al.
Publicado: (2017)

Effect of octanoic acid-rich formula on plasma ghrelin levels in cachectic patients with chronic respiratory disease
por: Ashitani, Jun-ichi, et al.
Publicado: (2009)

The effects of postprandial glucose and insulin levels on postprandial endothelial function in subjects with normal glucose tolerance
por: Suzuki, Kazunari, et al.
Publicado: (2012)

Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study
por: Ito, Daisuke, et al.
Publicado: (2017)

Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin
por: Choi, Min-Koo, et al.
Publicado: (2020)

Clinical features and electrocardiogram parameters in Parkinson’s disease
por: Mochizuki, Hitoshi, et al.
Publicado: (2017)

Periodic Blood Pressure Fluctuations in Undiagnosed Pheochromocytoma
por: Uehira, Yudai, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c6bs4ve24g8f6103dvl0h5ot7v